2021 Update: The Melanoma Research Alliance (MRA) staff in partnership with twenty-one academic co-authors have published a review article: Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration–Melanoma Research Alliance Public Workshop, in Clinical Cancer Research.
The review covers lessons learned from neoadjuvant approaches in breast and lung cancer, and early melanoma trials. The review summarizes potential benefits and risks of neoadjuvant approaches to melanoma, integration with surgery, clinical trial design and regulatory considerations, biomarkers, and challenges and future research directions. This review article provides a succinct summary of neoadjuvant treatments in melanoma.
The article can be freely downloaded here: https://clincancerres.aacrjournals.org/content/27/2/394.long
On November 6, 2019, the FDA and the Melanoma Research Alliance co-hosted a public workshop to identify, discuss, and address key issues, challenges and opportunities in the pursuit of neoadjuvant therapies for patients with surgically resectable melanoma. This exciting, half-day workshop brought together clinicians, researchers, regulators, and patient advocates to explore opportunities and discuss challenges in the development of neoadjuvant therapies for melanoma. The workshop took place at National Harbor (outside of Washington, D.C.) with opportunities to participate in person and via simultaneous webcast.
Presentation 1: Dr. Suzanne Topalian
Presentation 2: Dr. Angela DeMichele
Presentation 3: Dr. Patricke Forde
Presentation 4: Dr. Laleh Amiri-Kordestani
Presentation 5: Dr. Donald Berry
Presentation 6: Dr. Caroline Robert
Presentation 7: Dr. Jennifer Wargo
Presentation 8: Dr. Janis Taube
Presentation 9: Dr. Charlotte Ariyan
Presentation 10: Dr. Michael Atkins
Presentation 11: Dr. Christian Blank
Presentation 12: Dr. Rajeshwari Sridhara
